PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

被引：0
|
作者：
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
le Coutre, Philipp D.
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Rea, Delphine
Abruzzese, Elisabetta
Mueller, Martin C.
Baccarani, Michele
Gambacorti-Passerini, Carlo
Turner, Christopher D.
Haluska, Frank G.
Kantarjian, Hagop
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Catholic Univ Korea, Seoul, South Korea
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[5] Charite, D-13353 Berlin, Germany
[6] Singapore Gen Hosp, Singapore, Singapore
[7] Ctr Hosp Lyon Sud, Pierre Benite, France
[8] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[9] Emory Winship Canc Inst, Atlanta, GA USA
[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[11] Washington Univ, Sch Med, St Louis, MO USA
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
[13] Hop St Louis, Serv Malad Sang, Paris, France
[14] Osped S Eugenio, Rome, Italy
[15] Heidelberg Univ, Med Fak Mannheim, Med Klin 3, Mannheim, Germany
[16] Univ Hosp Bologna, Bologna, Italy
[17] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy
[18] ARIAD Pharmaceut, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6503
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy study of subcutaneous homoharringtonine (SC HHT) in imatinib (IM)-resistant chronic myeloid leukemia (CML) with the T315I mutation - Initial report of a phase II trial
    Khoury, H. Jean
    Michallet, Mauricette
    Corm, Selim
    Roy, Lydia
    Jones, Dan
    Hochhaus, Andres
    Kantarjian, Hagop
    Benichou, Annie-Claude
    Scwartz, Richard
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 318A - 318A
  • [22] Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study
    Kensuke Usuki
    Arinobu Tojo
    Yasuhiro Maeda
    Yukio Kobayashi
    Akira Matsuda
    Kazuma Ohyashiki
    Chiaki Nakaseko
    Tatsuya Kawaguchi
    Hideo Tanaka
    Koichi Miyamura
    Yasushi Miyazaki
    Shinichiro Okamoto
    Kenji Oritani
    Masaya Okada
    Noriko Usui
    Tadashi Nagai
    Taro Amagasaki
    Aira Wanajo
    Tomoki Naoe
    International Journal of Hematology, 2012, 95 : 409 - 419
  • [23] A PHASE I/II STUDY OF NILOTINIB IN JAPANESE PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Usuki, K.
    Urabe, A.
    Tojo, A.
    Maeda, Y.
    Kobayashi, Y.
    Jinnai, I.
    Ohyashiki, K.
    Nishimura, M.
    Kawaguchi, T.
    Tanaka, H.
    Miyamura, K.
    Miyazaki, Y.
    Hughes, T.
    Branford, S.
    Okamoto, S.
    Ishikawa, J.
    Okada, M.
    Usui, N.
    Amagasaki, T.
    Natori, H.
    Naoe, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 433 - 434
  • [24] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL)
    Larson, R.
    Ottman, O.
    Kantarjian, H.
    le Coutre, P.
    Baccarani, M.
    Weitzman, A.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL) Patients
    Nicolini, Franck Emmanuel
    Zhou, Wei
    Martinelli, Giovanni
    Mauro, Michael J.
    Hochhaus, Andreas
    Su, Jing
    Apperley, Jane
    Chuah, Charles
    Dufva, Inge
    Kim, Dong-Wook
    Giles, Francis J.
    Peter, Senaka
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 268 - 268
  • [26] Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph plus ) CML/ALL patients.
    Greer, Devon M.
    Liewer, Susanna
    Akhtari, Mojtaba
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
  • [28] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
    Cortes, Jorge
    Lipton, Jeff H.
    Rea, Delphine
    Digumarti, Raghunadharao
    Chuah, Charles
    Nanda, Nisha
    Benichou, Annie-Claude
    Craig, Adam R.
    Michallet, Mauricette
    Nicolini, Franck E.
    Kantarjian, Hagop
    BLOOD, 2012, 120 (13) : 2573 - 2580
  • [29] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without the T315I Mutation
    Levy, Moshe Y.
    Mauro, Michael J.
    Issa, Ghayas C.
    Andorsky, David
    Tomassetti, Sarah
    Broun, E. Randolph
    Maegawa, Rodrigo
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S298 - S298
  • [30] FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation
    Pamuk, Gulsum E.
    Chow, Edwin C. Y.
    Ionan, Alexei C.
    Chen, Haiyan
    Lee, Shwu-Luan
    Hsu, Vicky
    Grimstein, Manuela
    Zheng, Nan
    Sun, Jielin
    Charlab, Rosane
    Gehrke, Brenda J.
    Vallejo, Jonathon
    Ehrlich, Lori A.
    de Claro, R. Angelo
    Theoret, Marc R.
    CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4266 - 4271
12345